INT278362

Context Info Confidence 0.21 First Reported 2009 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 2 Total Number 13 Disease Relevance 15.71 Pain Relevance 4.44

pigmentation (Hps5) cytoplasm (Hps5)

Hps5 (Mus musculus)

Pain Link Frequency Relevance Heat postherpetic neuralgia 312 99.92 Pain 228 99.04 Lasting pain 36 94.08 Shingles 12 82.48 Acute pain 12 77.64 depression 12 45.84 cytokine 10 5.00 Inflammation 8 5.00 Inflammatory response 4 5.00 chemokine 3 5.00

Disease Link Frequency Relevance Heat Herpes Zoster 1824 100.00 Post Operative Pain 312 99.92 Disease 270 99.52 Pain 228 99.04 Chickenpox 24 94.60 Death 61 93.36 Sprains And Strains 49 91.20 Influenza Virus Infection 168 89.72 Exanthema 72 89.40 Immunization 36 84.76

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The ROS scavenger, N-acetylcysteine (NAC) inhibited both Hz- and MSU-induced IL-1?

Negative_regulation (inhibited) of Hz

1) Confidence 0.21 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2722371 Disease Relevance 0 Pain Relevance 0

In the scenario based on the reduction of HZ only, the reduction of HZ and subsequent QALY loss was included.

Negative_regulation (reduction) of HZ associated with herpes zoster

2) Confidence 0.04 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.10 Pain Relevance 0.44

In the scenario based on the reduction of HZ only, the reduction of HZ and subsequent QALY loss was included.

Negative_regulation (reduction) of HZ associated with herpes zoster

3) Confidence 0.04 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.06 Pain Relevance 0.38

The vaccine has been registered in the EU as a single dose vaccine for the prevention of HZ and PHN among people aged 50 years or older.

Negative_regulation (prevention) of HZ associated with herpes zoster and postherpetic neuralgia

4) Confidence 0.04 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.52 Pain Relevance 0.31

In the scenario with reduction of HZ cases only the cost-effectiveness ratio increases towards ~€33500 at the age of 70; using the scenario with reduction of PHN improves the cost-effectiveness to a ratio of ~€10000.

Negative_regulation (reduction) of HZ associated with herpes zoster and postherpetic neuralgia

5) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 0.41 Pain Relevance 0.17

Presently, a vaccine to prevent HZ is available [2].

Negative_regulation (prevent) of HZ associated with herpes zoster

6) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 2.30 Pain Relevance 0.41

Although the clinical trial showed a higher impact of vaccination on the BOI compared to the incidence of HZ, we want to mention that using BOI or PHN endpoints will be more sensitive towards the decisions made in the way the QALY loss due to HZ is currently modeled/estimated.

Negative_regulation (loss) of HZ associated with herpes zoster and postherpetic neuralgia

7) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 0.65 Pain Relevance 0.19

Only one vaccine (ZOSTAVAX®; SP-MSD) has been registered for the prevention of HZ.

Negative_regulation (prevention) of HZ associated with herpes zoster

8) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 2.21 Pain Relevance 0.36

In the scenario based on the reduction of HZ only, the reduction of HZ and subsequent QALY loss was included.

Negative_regulation (loss) of HZ associated with herpes zoster

9) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.06 Pain Relevance 0.39

There are no direct alternatives to prevent HZ.

Negative_regulation (prevent) of HZ associated with herpes zoster

10) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 2.52 Pain Relevance 0.70

The duration of pain by severity and age, and subsequently the QALY loss due to HZ, was estimated by Van Hoek et al [28] and applied to the Dutch situation.

Negative_regulation (loss) of HZ associated with pain and herpes zoster

11) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.28 Pain Relevance 0.62

In the scenario describing the reduction of BOI, a reduction of QALY loss for the first 6 months in people with disease was included above the reduction in HZ cases (this is because the vaccine reduces disease severity in cases where HZ occurs in spite of vaccination).

Negative_regulation (reduction) of HZ associated with herpes zoster and disease

12) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.10 Pain Relevance 0.39

Vaccine effectiveness, reflected by the reduction of the incidence of HZ, PHN and related hospitalizations, could be monitored using GP and hospitalization statistics.

Negative_regulation (reduction) of HZ associated with herpes zoster and postherpetic neuralgia

13) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 0.50 Pain Relevance 0.10

General Comments

This test has worked.